Investor Relations


Triple-Gene Presentation - American Heart Association (AHA) Scientific Sessions
 Sunday, November 17, 2019
 3:00pm - 3:30pm EST

Intrexon subsidiary Triple-Gene presented preliminary data from the Phase 1 study of INXN-4001, a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure, at the American Heart Association Scientific Sessions at the Pennsylvania Convention Center in Philadelphia.  A poster titled “Safety of First in Human Triple-Gene Therapy Candidate for Heart Failure Patients” was presented on Sunday, November 17th.